Clinical Trials Logo

Clinical Trial Summary

This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.


Clinical Trial Description

This is a Phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors including ovarian, breast, lung, esophageal, gastric, hepatocellular and urothelial cancers. The study will determine any dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), assessing safety and preliminary efficacy using ascending dose cohorts and a conventional 3+3 study design. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05060276
Study type Interventional
Source Sorrento Therapeutics, Inc.
Contact Mike Royal, MD
Phone (858)203-4100
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date December 2021
Completion date December 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Not yet recruiting NCT05054348 - Dose Escalation Study of IO-108 and IO-108+Pembrolizumab in Solid Tumors Phase 1
Recruiting NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies Phase 1/Phase 2
Not yet recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Recruiting NCT04526106 - First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors Phase 1
Recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Recruiting NCT04315246 - 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors Phase 1/Phase 2
Recruiting NCT04092673 - Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT04130516 - Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and With Pembrolizumab Phase 1/Phase 2
Active, not recruiting NCT04041310 - Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Phase 1
Not yet recruiting NCT04597541 - A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT04165330 - Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Phase 1/Phase 2
Completed NCT04515043 - EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) Phase 1
Recruiting NCT03600090 - Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer Phase 1
Not yet recruiting NCT05036226 - COAST Therapy in Advanced Solid Tumors and Prostate Cancer Phase 1/Phase 2